Replies to post #1480 on GTC Biotherapeutics (fka GTCB)

[keitern]

We should try to quantify the leverage we have with our efficient production platform. I love the fact that we can find drug X out there that is super expensive and already approved and in use but with patent rights set to expire within a window. Sorry if I missed it but is there a list of candidates that fit this profile posted somewhere?

Risk is key in the market. If we do have a robust target list and if our researchers and engineers do have a high level of control in producing known proteins, then I think the market will come to appreciate this combination in time.

I am contemplating the term "bleeding edge" vis. GTCB. I know we are pioneers, but I don't think the term is quite justified here.

[jessellivermore]

Great post..................,,,,,,,,,

Keitern this is a wonderfully clear and concise summation of what GTCB and the transgenic platform is all about. The "cascade" is:

(1) transgenic platform ---------->lower production costs + increased yields
(2) lower production cost + increased yield --------> greater availability
(3) greater availability --------> increased clinical use.

This holds for both established or new clinical moieties.